Frontlight ResearchEarly access
TerminatedPhase 1
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Key facts
- Who runs it
- Mirati Therapeutics Inc.
- Where
- Baltimore, Boston, Fairfax, Grand Rapids, Houston, Lady Lake, Nashville, New Haven, New York, Phoenix, San Antonio, and Seattle, United StatesSee the 14 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 63 people enrolled
- Started
- 6 Mar 2023
- Ended
- 10 Mar 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- MRTX1133
- Record updated
- 6 April 2025
- Why it stopped
- Formulation challenges
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA
- Unresectable or metastatic disease
- Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts
- Presence of tumor lesions to be evaluated per RECIST v1.1:; in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease; in the Phase 1b and Phase 2 cohorts, patients must have measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
- Age ≥ 18 years
Who cannot take part
- Prior treatment with a KRAS G12D inhibitor (Phase 1b \& Phase 2 only)
- History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications
- History of malignant small bowel obstruction
- Cardiac abnormalities
- Active brain metastases or carcinomatous meningitis
Where in United States
- Baltimore, MarylandHospital not named in the registry
- Boston, MassachusettsHospital not named in the registry
- Boston, MassachusettsHospital not named in the registry
- Fairfax, VirginiaHospital not named in the registry
- Grand Rapids, MichiganHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Lady Lake, FloridaHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
- New Haven, ConnecticutHospital not named in the registry
- New YorkHospital not named in the registry
- Phoenix, ArizonaHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- Seattle, WashingtonHospital not named in the registry
About the trial
What the trial wants to find out
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
The 2 groups in the trial
- Phase 1/1BTreatment being tested
Dose Escalation/Evaluation
Treatment: MRTX1133
- Phase 2Treatment being tested
MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC, PDAC, CRC, Other Solid Tumors
Treatment: MRTX1133
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Publications
- Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.JCO oncology practice, 2024
- Record updated
- 6 April 2025